Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen’s diabetes therapy also will undergo discussions about renal and bone fracture risks during a Jan. 10 meeting of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.